Immuron files FDA application for deadly C. diff infection fight

Immuron has filed a pre-investigational new drug application with the United States Food and Drug Administration for IMM-529, designed as a new therapeutic to prevent and treat recurrent Clostridioides difficile infection

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.